The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. The NCTN serves as the NCI’s primary infrastructure to conduct phase II and III clinical trials.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Drug Discovery World

APRIL 29, 2024

Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma, pharmaceutical and clinical research (CRO) industries.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. million from Canada’s National Research Council (NRC) to support the clinical advancement of bacTRL-Spike.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

JANUARY 19, 2024

When alpha-emitting radionuclides are delivered to cancer cells, the emitted alpha particles cause substantial damage to the DNA of the cells, leading to cell death. For example, non-target effects such as the release of damaged DNA into the cytoplasm of irradiated cells can lead to the activation of immune cells.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

OCTOBER 7, 2022

Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. RA: Could you tell us about Cancer Research Horizons? . This is about changing how we operate. Hamish Ryder.

HR 52

HR Research Drugs Development 52

Drug Discovery World

JUNE 5, 2023

The panel was moderated by Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL. How can a biotech begin to shape and mould its culture, into something new and established? We started about three years ago and since then, we’ve been on a growing journey of fundraising and expanding the team.

Genome 52

Genome Genomics Life Science Genetics 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 30, 2023

Lonza’s integrated CMC strategy and timeline was presented, as well as case studies highlighting key approaches and technologies, including: vector design & integration, cell line selection, downstream process, analytical method and formulation development. kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

MARCH 6, 2024

They also involve multiple mutations in non-coding regions of DNA – the ‘dark genome’ which makes up around 98% of our DNA. Due to this underlying complexity, and despite major research efforts, effective preventative and disease-modifying treatments are yet to materialise for diseases such as ALS, Alzheimer’s and Parkinson’s.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

XTalks

FEBRUARY 3, 2021

Johnson & Johnson’s single-shot DNA vaccine candidate was shown to have an overall effectiveness of 66 percent in preventing moderate to severe COVID-19. Johnson & Johnson’s DNA Vaccine. The DNA vaccine was created using Janssen’s AdVac technology platform that is designed for rapid vaccine development.

Vaccination 103

Vaccination Vaccine Trials Protein 103

XTalks

OCTOBER 26, 2023

Kierstead joined PPD in 2009 and is currently an executive director of the vaccine sciences lab. She has 23 years of experience working with clients to move vaccine candidates through the clinical development pipeline, including regulatory submission. It worked in the favor of vaccine makers that X.BB.1.5

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. 5) Lynparza (Olaparib) Lynparza is a PARP inhibitor , meaning it inhibits poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. billion RMB ($34.47

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Delveinsight

JULY 29, 2020

Bharat Biotech International Limited (BBIL) is working in collaboration with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), Pune for COVAXIN which is the first indigenous Covid-19 vaccine candidate in india. Zydus has started the human clinical trials of its plasmid DNA based vaccine, ZyCoV-D.

Vaccination 62

Vaccination Vaccine Clinical Trials Clinical Trials 62

XTalks

SEPTEMBER 14, 2020

The most promising news about any drug thus far in the pandemic just came out of the UK where Southampton researchers together with Synairgen showed that an inhaled form of interferon-? helped protect COVID-19 patients against developing severe disease. Drugs and Vaccines. COVID-19: Future and Predictions.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92